Abstract:PURPOSE: We introduce two validated single (SH) and dual hormone (DH) mathematical models that represent an in-silico virtual patient population (VPP) for type 1 diabetes (T1D). The VPP can be used to evaluate automated insulin and glucagon delivery algorithms, so-called artificial pancreas (AP) algorithms that are currently being used to help people with T1D better manage their glucose levels. We present validation results comparing these virtual patients with true clinical patients undergoing AP control and demonstrate that the virtual patients behave similarly to people with T1D.METHODS: A single hormone virtual patient population (SH-VPP) was created that is comprised of eight differential equations that describe insulin kinetics, insulin dynamics and carbohydrate absorption. The parameters in this model that represent insulin sensitivity were statistically sampled from a normal distribution to create a population of virtual patients with different levels of insulin sensitivity. A dual hormone virtual patient population (DH-VPP) extended this SH-VPP by incorporating additional equations to represent glucagon kinetics and glucagon dynamics. The DH-VPP is comprised of thirteen differential equations and a parameter representing glucagon sensitivity, which was statistically sampled from a normal distribution to create virtual patients with different levels of glucagon sensitivity. We evaluated the SH-VPP and DH-VPP on a clinical data set of 20 people with T1D who participated in a 3.5-day outpatient AP study. Twenty virtual patients were matched with the 20 clinical patients by total daily insulin requirements and body weight. The identical meals given during the AP study were given to the virtual patients and the identical AP control algorithm that was used to control the glucose of the virtual patients was used on the clinical patients. We compared percent time in target range (70-180 mg/dL), time in hypoglycemia (<70 mg/dL) and time in hyperglycemia (>180 mg/dL) for both the virtual patients and the actual patients.RESULTS: The subjects in the SH-VPP performed similarly vs. the actual patients (time in range: 78.1 ± 5.1% vs. 74.3 ± 8.1%, p = 0.11; time in hypoglycemia: 3.4 ± 1.3% vs. 2.8 ± 1.7%, p = 0.23). The subjects in the DH-VPP also performed similarly vs. the actual patients (time in range: 75.6 ± 5.5% vs. 71.9 ± 10.9%, p = 0.13; time in hypoglycemia: 0.9 ± 0.8% vs. 1.3 ± 1%, p = 0.19). While the VPPs tended to over-estimate the time in range relative to actual patients, the difference was not statistically significant.CONCLUSIONS: We have verified that a SH-VPP and a DH-VPP performed comparably with actual patients undergoing AP control using an identical control algorithm. The SH-VPP and DH-VPP may be used as a simulator for pre-evaluation of T1D control algorithms.

Mapping data to virtual patients in type 1 diabetes

Generative deep learning for the development of a type 1 diabetes simulator

Developing the UVA/Padova Type 1 Diabetes Simulator: Modeling, Validation, Refinements, and Utility

A statistical virtual patient population for the glucoregulatory system in type 1 diabetes with integrated exercise model

Approaches to Modeling Blood Glucose Dynamics In Type 1 Diabetic Patients for Insulin Pump Automation

Modeling Physical Activity Impact on Glucose Dynamics in People with Type 1 Diabetes for a Fully Automated Artificial Pancreas

Learning Insulin-Glucose Dynamics in the Wild

Predictive Glucose Monitoring for Type 1 Diabetes Using Latent Variable-Based Multivariate Statistical Analysis

The Safety Challenges of Deep Learning in Real-World Type 1 Diabetes Management

Study of Short-Term Personalized Glucose Predictive Models on Type-1 Diabetic Children

In-silico Risk Analysis of Personalized Artificial Pancreas Controllers via Rare-event Simulation

Machine Learning-Based Time in Patterns for Blood Glucose Fluctuation Pattern Recognition in Type 1 Diabetes Management: Development and Validation Study

Blood Glucose Level Forecasting on Type-1-Diabetes Subjects during Physical Activity: A Comparative Analysis of Different Learning Techniques

Reinforcement Learning: A Paradigm Shift in Personalized Blood Glucose Management for Diabetes

Towards the Integration of an Islet-Based Biosensor in Closed-Loop Therapies for Patients With Type 1 Diabetes

Automated Insulin Delivery for Type 1 Diabetes Mellitus Patients using Gaussian Process-based Model Predictive Control

Learning Carbohydrate Digestion and Insulin Absorption Curves Using Blood Glucose Level Prediction and Deep Learning Models

Dynamic flux balance analysis of whole-body metabolism for type 1 diabetes

A metamodel-based flexible insulin therapy for type 1 diabetes patients subjected to aerobic physical activity

Interpretable Mechanistic Representations for Meal-level Glycemic Control in the Wild

Simulation-driven optimization of insulin therapy profiles in a commercial hybrid closed-loop system